Portland, OR, July 15, 2011 --(PR.com
)-- VetSource is pleased to announce that KINAVET-CA1 (masitinib mesylate), a new treatment option to address severe mast cell tumors in dogs, is now available. Kinavet is an exciting new option for veterinarians and pet owners to manage and reduce this common form of canine skin cancer.
Kinavet has been granted conditional approval by the U.S. Food & Drug Administration as safe and effective at delaying tumor progression in canines. This powerful new treatment option was developed by AB Science to help reduce symptoms and increase survival. While Kinavet will not cure the disease, it can help manage the disease and improve the pet’s quality of life.
Kinavet contains mastinib, an anti-cancer drug designed for use with dogs suffering from aggressive mast cell tumors (mastocytoma). Mastinib is a protein- tyrosine kinase inhibitor that blocks enzymes that cause mast cells to divide uncontrollably. By blocking these receptors, Kinavet helps control cell division and prevents further tumor developments with this particular mutation.
Kinavet is unique because unlike other forms of chemotherapy treatments, it comes in a convenient tablet form that can be given at home. This exciting new product is available to order from VetSource via ScriptRightTM, call-in orders, or participating veterinarian e-commerce sites.
For more information contact VetSource customer service or our Pharmacy.
VetSource services are marketed throughout the United States via its partnership with Webster Veterinary (a Patterson Company).
About VetSource: VetSource, is a North American leader in the home delivery of companion-animal pharmaceutical products and pet nutrition. The company works with veterinarians to enhance the veterinarian-client-patient relationship by supporting practitioners through professional pharmacy services. For more information, please visit www.vetsource.com, call 503-802-7400, or contact your Webster Representative.